BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
Scientists are conducting a study on a new way to help treat multiple myeloma, a type of cancer. They are using special cells from the patient's own body that have been changed to fight the cancer better. They want to see if this new treatment is safe and can help people with this type of cancer.
Scientists are conducting a study on a new way to help treat multiple myeloma, a type of cancer. They are using special cells from the patient's own body that have been changed to fight the cancer better. They want to see if this new treatment is safe and can help people with this type of cancer.
*Third Opinion AI Generated Synopsis
Trial Summary
This is a first-in-human study to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous T cells genetically engineered with a novel B-cell Maturation Antigen (BCMA)-specific chimeric antigen receptor (CAR) and manufactured with a new process. CAR-T cells will be investigated as a single agent in multiple myeloma
This is a first-in-human study to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous T cells genetically engineered with a novel B-cell Maturation Antigen (BCMA)-specific chimeric antigen receptor (CAR) and manufactured with a new process. CAR-T cells will be investigated as a single agent in multiple myeloma
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: